Effect of glycosylation on antibody function: implications for genetic engineering

Monitoring impurities in biopharmaceuticals produced by recombinant technology

The unique nature of recombinant technology and the biotherapeutic production process means that regulatory agencies around the world not only require extensive characterization of the product, but they have also provided 'guidelines' to control and monitor product- and process-derived impurities and contaminants. Not only might these impurities and contaminants have a profound effect on product quality and efficacy, but they might also introduce unwanted and unknown side effects, even in trace amounts. The authors present a comprehensive understanding of the nature of possible product- and process-related impurities, and also describe current and future methodologies to control and monitor these impurities.

N-glycosylation influences epitope expression and receptor binding structures in human IgE

Although human IgE is relatively rich in carbohydrates, there are few studies concerning their structural and functional importance. The low serum concentration of IgE has limited carbohydrate characterisation to a few IgE myeloma proteins. Four to six of the seven potential N-glycosylation sites in the constant region of the epsilon chain seem occupied together with some residual microheterogeneity. We have used a panel of 28 anti-Cepsilon2, 7 anti-Cepsilon3 and 18 anti-Cepsilon4 domain-specific anti-IgE mAbs, and rFcepsilonRIalpha to examine the effect of N-glycosylation on epitope expression of human IgE. Myeloma proteins IgE(DES)-kappa, IgE(ND)-lambda and IgE(UD)-kappa as well as polyclonal IgE were deglycosylated with PNGF and/or sialidase and tested in different ELISA. In all ELISA approaches, the reactivity of most domain-specific anti-IgE mAbs was independent of the glycosylation state of IgE(DES), except for one-third of the anti-Cepsilon2 mAbs. These mAbs reacted better with deglycosylated IgE(DES) in the order of treatment PNGF/sialidase > PNGF > or = sialidase > buffer control. In sharp contrast, the reactivity of IgE(DES) with rFcepsilonRIalpha was not influenced by sialidase but markedly reduced following PNGF or PNGF/sialidase treatment. These findings were neither myeloma restricted nor caused by aggregation, since monomeric IgE demonstrated the same reactivity pattern. Thus. N-glycosylation seems to influence both structure and function of human IgE. The oligosaccharides modulate epitope expression, mainly in the Cepsilon2-domain, as revealed by a subset of mAbs. They also promote subtle changes in the Cepsilon3-domain, leading to a reduced FcepsilonRIalpha binding. These findings suggest physiological implications of carbohydrates in human IgE.

High-resolution polyacrylamide gel electrophoresis of carbohydrates derivatized with a visible dye

A technique for carbohydrate analysis that is both inexpensive and easily performed is currently unavailable. In this communication we address the problem and have outlined a method for labeling saccharides with a visible dye, 4-amino-1,1'-azobenzene-3, 4'-disulfonic acid, which has an absorption maximum of 489 nm and an extinction coefficient of 37,615, to facilitate visible detection at low levels. The visible dye was coupled by a reductive amination to different sugars. The sugar-dye adducts were then separated by electrophoresis on alkaline polyacrylamide gels. The gels were scanned with a densitometer, and visible sugar-dye adducts were qualitatively analyzed by identifying them according to their mobilities. The sugar-dye adducts were quantified by determining their densitometric volume. The kinetics of the reductive amination reactions, performed at 37 degrees C, were different for each of three saccharides tested. The rate constants for glucose and fucose were 1.31 times greater and 1.8 times greater, respectively, than that of maltotriose. The reductive amination reactions were essentially complete after approximately 16 h under the given experimental conditions. A linear dose-response relationship was observed between the amount of sugar (monosaccharide, trisaccharide, or heptasaccharide) in the reductive amination reaction. The quantity of saccharide-dye adduct that could be visually detected for glucose, maltotriose, and maltoheptaose, was 25, 25, and 50 nmol, respectively. Sugar-dye adducts were separated from one another by varying the acrylamide concentration in the polyacrylamide gels. Sugar-dye adducts of monosaccharides, disaccharides, trisaccharides, and heptasaccharides were separated on alkaline 30% polyacrylamide gels with mobilities of 0.778, 0.667, 0.639, and 0.375. Adducts of glucose, fucose, galactose, and mannose were separated with mobilities of 0.844, 0.833, 0.820, and 0.810, respectively, on a 30 to 40% gradient polyacrylamide gel. Adducts of glucose and glucose derivatives were separated on a 35% polyacrylamide gel. This technique provides an inexpensive and easily performed method of carbohydrate analysis to laboratories that do not have the highly trained personnel nor the expensive equipment needed for other methods of carbohydrate analysis. The method is most applicable to research problems where sensitivity (20 pmol) is not a problem. The simplicity of the method also makes it easily incorporated into teaching laboratories.

A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes

The ability to produce monoclonal antibodies (Mabs) in plants offers the opportunity for the development of an inexpensive method of mucosal immunoprotection against sexually transmitted diseases. To investigate the suitability of plant-expressed Mabs for vaginal preventive applications, we compared a humanized anti-herpes simplex virus 2 (HSV-2) Mab expressed in mammalian cell culture with the same antibody expressed in soybean. We found these Mabs to be similar in their stability in human semen and cervical mucus over 24 h, their ability to diffuse in human cervical mucus, and their efficacy for prevention of vaginal HSV-2 infection in the mouse.

The effect on IgG glycosylation of altering beta1, 4-galactosyltransferase-1 activity in B cells

An absence of galactose on the N-linked oligosaccharides of immunoglobulin G (IgG) has been shown to affect the functional activity of the antibody molecule. In patients with rheumatoid arthritis there is an increased proportion of IgG which lacks galactose and correspondingly lower levels of beta1, 4-galactosyltransferase (beta4Gal-T) activity. The recent demonstration of several expressed beta4Gal-T genes in man raises the possibility that the enzyme responsible for the decreased IgG galactose is not the "classical" beta4Gal-T (beta4Gal-T1). To directly address the question of whether reduced beta4Gal-T1 would lead to reduced IgG galactose, the level of beta4Gal-T1 in a human IgG-secreting B cell line was specifically altered using stable transfection with sense (SpcDNA3-Gal-T1) or antisense (ASpcDNA3-Gal-T1) human beta4Gal-T1 cDNA. SpcDNA3-Gal-T1 B cell transfectants expressed up to a 2.5-fold higher level of beta4Gal-T enzyme activity for the exogenous neoglycoconjugate acceptor GlcNAc-pITC-BSA than did ASpcDNA3-Gal-T1 transfectants. Flow cytometric analysis with Ricinus communis agglutinin I (RCAI) revealed an overall greater number of Galbeta1,4GlcNAc structures in the fixed and permeabilized SpcDNA3-Gal-T1 B cell transfectants compared with the ASpcDNA3-Gal-T1 transfectants. Moreover, there was increased galactosylation of IgG secreted from the SpcDNA3-Gal-T1 transfectants relative to the ASpcDNA3-Gal-T1 B cell transfectants. Alteration of the level of the "classical" beta4Gal-T (beta4Gal-T1) in B cells therefore affects IgG glycosylation.

The role of glycosylation in autoimmune disease

Oligosaccharide structures play a key role in the antigenicity of a number of clinically important antigens such as blood group determinants. Interest in glycobiology has increased dramatically amongst immunologists during the last few years due to the fact that oligosaccharides also play a central role in adhesion and homing events during inflammatory processes (1), comprise powerful xenotransplantation antigens (2), and may provide targets for tumor immunotherapy (3). Additionally, alterations in glycosylation are now known to occur in a number of autoimmune diseases. This review will first discuss some general aspects of protein glycosylation and then explore some of the autoimmune diseases in which the role of glycosylation has been examined.

IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation

The Fc region of human IgG expresses interaction sites for many effector ligands. In this review the topographical distributions of ten of these sites are discussed in relation to functional requirement. It is apparent that interaction sites localised to the inter-CH2-CH3 domain region of the Fc allow for functional divalency, whereas sites localised to the hinge proximal region of the CH2 domain are functionally monovalent, with expression of the latter sites being particularly dependent on glycosylation. All x-ray crystal structures for Fc and Fc-ligand complexes report that the protein structure of the hinge proximal region of the CH2 domain is "disordered", suggesting "internal mobility". We propose a model in which such "internal mobility" results in the generation of a dynamic equilibrium between multiple conformers, certain of which express interaction sites specific to individual ligands. The emerging understanding of the influence of oligosaccharide/protein interactions on protein conformation and biological function of IgG antibodies suggests a potential to generate novel glycoforms of antibody molecules having unique profiles of effector functions.